25 février 2022 – EMA has recommended granting a marketing authorisation for Kimmtrak (tebentafusp) in the European Union (EU), a monotherapy for the treatment of adult patients with uveal melanoma, a rare type of eye cancer. The most common side effects of the new medicine observed in clinical trials were skin rashes, fever and itching.

For more information, see here.